glutamine has been researched along with olaparib in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chaves, F; Christodoulou, D; Gameiro, PA; Iliopoulos, O; Laviollette, L; Lee, R; Okazaki, A; Schneider, M; Stemmer-Rachamimov, A; Stephanopoulos, G; Yazinski, SA; Zou, L | 1 |
| Asaka, R; Asaka, S; Attarwala, N; Chen, X; Chen, YW; Chuang, CM; Davidson, B; DeMarzo, AM; Gaillard, S; Hong, J; Hsu, FC; Jung, JG; Le, A; Shen, YA; Shih, IM; Suryo Rahmanto, Y; Tomaszewski, A; Wang, TL; Yen, TT; Zhang, C | 1 |
2 other study(ies) available for glutamine and olaparib
| Article | Year |
|---|---|
Glutaminase and poly(ADP-ribose) polymerase inhibitors suppress pyrimidine synthesis and VHL-deficient renal cancers.
Topics: Animals; Carcinoma, Renal Cell; Glutamates; Glutaminase; Glutamine; Humans; Kidney Neoplasms; Mice; Mice, Nude; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Reactive Oxygen Species; S Phase Cell Cycle Checkpoints; Von Hippel-Lindau Tumor Suppressor Protein; Xenograft Model Antitumor Assays | 2017 |
Inhibition of the MYC-Regulated Glutaminase Metabolic Axis Is an Effective Synthetic Lethal Approach for Treating Chemoresistant Ovarian Cancers.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzeneacetamides; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Glutaminase; Glutamine; Glutathione; Humans; Mice, Nude; Ovarian Neoplasms; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Proto-Oncogene Proteins c-myc; Thiadiazoles; Xenograft Model Antitumor Assays | 2020 |